Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for oncology and neurology. The company's lead product, NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel designed to treat non-muscle-invasive bladder cancer (NMIBC), specifically targeting BCG-unresponsive and intermediate-risk patients. NDV-01 is currently in Phase 2 clinical trials, with Phase 3 studies planned for initiation in mid-2026. The company's second program, sepranolone, is a neurosteroid epimer of allopregnanolone being developed for Prader-Willi syndrome, Tourette Syndrome, and essential tremor. Sepranolone is Phase 2b-ready, with a Phase 2b study in Prader-Willi syndrome expected to begin in mid-2026. Relmada acquired sepranolone from Asarina Pharma AB and in-licensed NDV-01 from Trigone Pharma Ltd. in early 2025. The company previously terminated its development of esmethadone (REL-1017) and a modified-release formulation of psilocybin (REL-P11) in 2025.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage relmada.com
Sector Healthcare IR page ir.relmada.com
Tags
oncology, neurology, bladder cancer, prader-willi syndrome, tourette syndrome, essential tremor, intravesical therapy, neurosteroids, clinical-stage, drug delivery, NDV-01, sepranolone, esmethadone, REL-1017, REL-P11, Asarina Pharma AB, Trigone Pharma Ltd.
Press page —

Metrics

Valuation  
Market cap $ 402.24M
Market cap (USD) $ 402.24M
P/E -5.24
PEG —
P/BV 2.08
P/S —
P/OCF -7.76
P/FCF -8.79
Dividend yield —
Turnover / mcap —
Returns  
ROE -94.0%
ROI -66.3%
ROIC -51.2%
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score -53.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2013 FY 2012
Revenue — — — — — — — — — — — 5.129K 7.941K
Net profit -57.385M -79.979M -98.792M -157.044M -125.752M -59.456M -17.318M -8.961M -6.287M -2.975M -20.804M -45.015K -12.052K
Free cash flow -45.787M -51.756M -51.659M -103.802M -91.873M -209.86M — -6.014M -6.516M -13.706M -16.25M -13.659K —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2013 FY 2012
Share price 4.83 0.52 4.14 3.49 22.53 32.07 1.5 — — 2.5 — — —
Price performance 12m 8.29 -0.87 0.19 -0.85 -0.3 -0.18 — — — — — — —

Filed figures

Figure Jun 2018 Dec 2018 Jun 2019 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — 512,432 — — —
Cash and deposits (USD) 2.24M 2.43M 9.22M 36.3M 2.5M 44.4M 5.4M 4.09M 3.86M 3.5M
Cash flow detail
Operating cash flow (USD) -6M — -10.5M -12.1M -27.8M -91.9M -104M -51.7M -51.8M -45.8M
Purchases of property, plant and equipment (USD) -12,391 — — -84.8M -182M — — — — —
Change in receivables (cash effect) (USD) — — — — — — -512,432 — — —
Change in payables (cash effect) (USD) 157,392 — 158,920 163,773 7.82M 2.85M 421,040 -1.76M 624,554 -2.56M
Interest paid (cash effect) (USD) -2,559 — -5,933 -9,034 -2,415 — — — — —
Share-based compensation (USD) 517,999 — 1.21M 3.17M 20.8M 40.5M 44.2M 43.8M 30.2M 13.9M
Operating cash flow before change in receivables (USD) — — — — — — -103M — — —
Free cash flow (OCF - PPE - intangibles) (USD) -6.01M — — -96.9M -210M — — — — —
Income detail
Research and development expense (USD) 2.94M — 7.02M 7.86M 36M 90.6M 113M 54.8M 46.2M 26.9M
↳ 5y CAGR +42.5% -5.7%
Reported Sep 28, 2018 Feb 13, 2019 Sep 24, 2019 Mar 24, 2021 Mar 24, 2021 Mar 23, 2023 Mar 23, 2023 Mar 19, 2024 Mar 27, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01

CORAL GABLES, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development across Relmada’s pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.

Dr. Jakobsen is an accomplished clinical development executive and board-certified urologist who served as the Head of Global Clinical Development for the pivotal program of Ferring Pharmaceuticals’ ADSTILADRIN® that culminated in approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and Health Canada for the treatment of non-muscle invasive bladder cancer (NMIBC).

● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance

● Long-term extension NDV-01 Phase 2 data demonstrate continued durability of response: 86% of 12-month complete responders remained in complete response at 18 months, with no Grade ≥3 treatment-related adverse events or discontinuations

● Registrational Phase 3 program renamed SPECTRUM; two independent registrational pathways in NMIBC remain unchanged

● Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026, expected to fund operations through 2029

CORAL GABLES, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. — Other Events Bull 0 Bear 0 Management

Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026.

1

Prompts

Relmada Therapeutics, Inc. (ticker RLMD), listed in United States.

Company History

Date Change Detail
Jul 24, 2014 Renamed CAMP NINE, INC. → RELMADA THERAPEUTICS, INC.

ETFs Holding Relmada Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 5.24% 663,176 $ 1.996M Nov 17, 2026
VFMO 0.06% 274,174 $ 1.195M Aug 31, 2026
AVSC 0.01% 82,977 $ 299.547K Nov 16, 2026
MSSM 0.00% 4,728 $ 20.614K Aug 31, 2026
DFAS 0.00% 2,078 $ 8,644.48 Nov 12, 2026